Provides a systematic framework for the recognition, evaluation, and management of resistant hypertension, particularly addressing the therapeutic gap in patients with chronic kidney disease.
No takes yet. Share an insight, caveat, or question.
Highlights evidence gap for resistant hypertension in CKD; leaves optimal strategies open pending dedicated trials.
Braam et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: